NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3027% below fair value

$11.83+0.11 (+0.94%)

Close on Nov 13, 2026Market cap $1.38BP/E –Yield –

NovoCure EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

NovoCure's EV/EBITDA was 446.8× on Oct 29, 2021, against 759.2× a year earlier.

Period	Period end	Value	Change (pts)
2021	Oct 29, 2021	446.8×	−182.4
2020	Dec 31, 2020	629.1×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NVCR.

Revenue growth12.9% · median 2.1%

Gross margin77.0% · median 70.9%

Operating margin-17.2% · median -2.5%

Net margin-16.8% · median -4.4%

Advertisement
300 × 250

See a number that looks wrong?